NEUROPHET Inc.
Financials
Valuation Metrics
NEUROPHET Inc.'s Market Cap is ₩848B. Ranked #1375 of 2,421 in KR market (top 57%), #773 of 1,640 on KOSDAQ (top 47%), #51 of 96 in Health Care Equipment & Services (top 53%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 84.78B KRW | KR#1,375/2,421 Sec#51/96 |
| Revenue | 2.62B KRW | KR#2,376/2,421 Sec#96/96 |
| Net Income | -22.39B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 26.88B KRW | KR#2,356/2,421 Sec#91/96 |
| Net Assets | 19.45B KRW | KR#2,295/2,421 Sec#88/96 |
| Value | ||
| P/B | 4.36x | KR#2,212/2,421 Sec#86/96 |
| P/S | 32.42x | KR#2,360/2,421 Sec#92/96 |
| FCF Yield | -18.08% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -115.10% | KR#2,356/2,421 Sec#91/96 |
| ROA | -83.28% | KR#2,391/2,421 Sec#96/96 |
| Op. Margin | -632.84% | KR#2,375/2,421 Sec#96/96 |
| Financial Health | ||
| Debt Ratio | 38.21% | KR#749/2,421 Sec#36/96 |
| Total Debt | 4.80B KRW | KR#1,801/2,421 Sec#66/96 |
| FCF | -15.33B KRW | KR#1,829/2,421 Sec#72/96 |
| Cash | 4.10B KRW | KR#2,074/2,421 Sec#80/96 |
| Current Ratio | 3.61x | KR#439/2,421 Sec#29/96 |
| Performance | ||
| 1Y Return | -57.75% | KR#2,176/2,421 Sec#79/96 |
| 1M Return | -13.66% | KR#2,213/2,421 Sec#84/96 |
| From 52W High | -81.06% | KR#2,354/2,421 Sec#91/96 |
| 1Y MDD | -83.11% | KR#2,342/2,421 Sec#92/96 |
| Trading | ||
| Volume | 31,372 shares | KR#1,363/2,421 Sec#49/96 |
| Trading Value | 220.1M KRW | KR#1,236/2,421 Sec#47/96 |
| Foreign Own. | 6.64% | KR#671/2,421 Sec#19/96 |
| Per Share | ||
| EPS | -1,835 KRW | KR—/2,421 Sec—/96 |
| BPS | 1,595 KRW | KR#2,168/2,421 Sec#77/96 |
Company Info
Neurophit was established in 2016 as a specialized AI solution company for brain diseases and is scheduled to be listed on KOSDAQ in 2025. The company develops AI technology-based brain image analysis software and therapeutic medical devices, providing full-cycle brain disease medical solutions from diagnosis to treatment. Neurophit possesses AQUA for degenerative brain disease diagnosis support, SCALE PET for PET image analysis, and AQUA AD for Alzheimer's solutions, while continuously conducting R&D in various brain disease fields such as depression treatment and brain MRI. Neurophit is headquartered in Gangnam-gu, Seoul.